LGALS3 and cancer: No significant differences in galectin-3 levels were noted before and after treatment (WMD = −0.10, 90% CI −6.06–5.85, I2: 99%), and a weaker relationship was observed between galectin-3 evaluations and cancer-therapy-related cardiotoxicity (HR = 1.39, 90% CI 0.97–1.98, I2: 0%).